AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Immunotherapeutics. There’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback